Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Collagen Solutions heading for pivotal year in 2018, says broker

A first partnership agreement was signed with a South Korean company towards the end of 2017
x-ray
The trial has been running for eight years

Regenerative med-tech Collagen Solutions PLC (LON:COS) is set for a significant year in 2018 as results of a long-running cartilage implant trial are published, says broker Cenkos.

ChondroMimetic, a collagen-based scaffold for the treatment of small defects in the articular surface of the knee joint, has been on trial with 15 patients since 2009/10.

READ: Collagen Solutions shares surge after it inks South Korea deal

The company expects to report key clinical data this quarter and assuming a positive outcome, will apply for a European regulatory CE mark and look for additional partners for the product later in the year, Cenkos said.

A first partnership agreement was signed with a South Korean company towards the end of 2017.

Third revenue arm

ChondroMimetic will be the start of a third leg to the business if approved.

Currently, Collagen derives its revenues from two sources: the supply of tissue and biomaterials to a medical use standard for implants and research; and development work on customer-specific products.

Margins have been falling lately, but Cenkos believes this reflects bespoke development work being undertaken ahead of future revenues.

“The development cycle from initial customer identification through to first market sales of the customer’s medical device can take up to four to five years, during which Collagen will move through periods when revenues are received and periods with no income.” 

With a developing customer pipeline, Cenkos, the house broker, also forecasts growth in the biomaterials business going forward.

Sales rising

Sales this year (March 2018) are forecast at £4.3mln, rising to £5.7mln in 2019 and £10.2mln in 2020 when Cenkos forecasts a first profit.

“We believe the company is also strengthening its existing business stating its sales pipeline is ‘the strongest it has been’. We maintain our Buy recommendation.”

Shares are 2.5p.

View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
1530537220_Blood-Test.jpg
July 02 2018
The research and diagnostic company develops cancer-detecting blood tests
Pharmaceuticals
June 28 2018
The AIM-listed pharmaceuticals developer said the contract delays meant that its first-half revenue was expected to be “below management’s expectations”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use